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Abstract: Several recently developed high-throughput techniques have changed the field of molecular
virology. For example, proteomics studies reveal complete interactomes of a viral protein, genome-
wide CRISPR knockout and activation screens probe the importance of every single human gene
in aiding or fighting a virus, and ChIP-seq experiments reveal genome-wide epigenetic changes in
response to infection. Deep mutational scanning is a relatively novel form of protein science which
allows the in-depth functional analysis of every nucleotide within a viral gene or genome, revealing
regions of importance, flexibility, and mutational potential. In this review, we discuss the application
of this technique to RNA viruses including members of the Flaviviridae family, Influenza A Virus
and Severe Acute Respiratory Syndrome Coronavirus 2. We also briefly discuss the reverse genetics
systems which allow for analysis of viral replication cycles, next-generation sequencing technologies
and the bioinformatics tools that facilitate this research.
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1. Introduction
In its essence, deep sequencing is a tool that allows the sequencing of a genomic
region multiple times. Deep mutational scanning (DMS) is a technique that utilises deep
sequencing technology in combination with a library of mutant genes or genomes pro-
duced by random mutagenesis to probe the functional effects of mutations at every single
nucleotide position within a gene or genome, linking genotype to phenotype in a single
high-throughput experiment. This technique has been applied to various proteins to reveal
residue-specific information regarding many aspects of protein biology. For example,
under certain conditions, replacement of a yeast gene with a mutant library of a human
orthologue can allow for determination of mutants which impact growth, and may be
linked to human disease [1,2]. Unbiased selection and identification of mutants with im-
proved properties or activities for specific requirements, such as increased solubility, have
furthered the field of protein engineering [3]. Numerous other applications have also been
pursued through DMS, including construction of complete functional activity landscapes
of genes [4,5], establishment of quantitative evolutionary models [6,7], and contributions
to structural biology [8,9]. In this review, we will predominantly focus on how DMS has
been applied to the study of viral replicative fitness and immune evasion in the context of
infectious virus replication cycles.
First, we should consider how residues and genomic regions of importance have been
analysed by point mutagenesis in the past. Many studies have utilised alanine substitution
to reveal residues or regions of importance in a viral protein. Commonly, residues for
mutation are selected by analysis of protein structure, conservation with other isolates or
strains, or amino acid biophysical properties [10,11]. Alternatively, large regions of interest
may be interrogated by alanine scanning mutagenesis as a less targeted approach [12,13].
Alanine mutagenesis is the preferred substitution, as alanine features an inert, non-bulky
methyl functional group, and does not alter main-chain conformation [14]. In these studies,
mutants of interest are typically loss-of-function mutants, as this is indicative of the absense
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of a functionally important residue. Experiments attempting to generate adaptive or gain-
of-function mutations often rely on serial passages of a virus in cell culture or animal
models [15–17], relying on an error-prone viral polymerase to generate mutants. A limiting
factor is that combinations of mutations that may be required to enhance viral fitness
in a given host may not be realised within the system. This method can also be time
consuming as multiple rounds of infection are required. In regard to analysis of the impact
of amino acid substitutions on viral protein function or viral replicative fitness, DMS can
allow the substitution of a given residue with all possible amino acids, increasing the
probability of identifying gain-of-function mutations that otherwise require more than one
nucleotide substitution.
DMS studies in virology are generally performed using a three-step approach. First, a
mutant library of a gene or genome of interest is prepared, ideally with genetic variants
encoding every single possible residue change within the sequence of interest. Second,
a selective pressure is applied to the library, enabling the enrichment of mutations that
encode a selective advantage and the removal of deleterious mutations. Finally, the
frequency of mutations within the library is quantified via next-generation sequencing
(NGS) and compared before and after the application of the selective pressure. In studies
of viral replicative fitness, a mutant with a cost to fitness will be selected against, while an
enhancing mutant, for example, an antiviral escape mutant, will become enriched. Selective
pressures, such as drug/antibody presence, stimulation of antiviral innate immunity,
growth in cell types of different species, and binding potential to a host receptor have been
applied to studies of many viral genes. Analysis of variants through DMS has enabled
evolutionary studies, escape mutant predictions, attenuated vaccine construction and other
applications. In this review, we will discuss various DMS strategies and how they have
been applied in virology, with a focus on the Flaviviridae family of viruses, Influenza Virus A
(IAV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). DMS studies
of RNA viruses have been made possible through the development of reverse genetics
systems, or easily modified infectious clones, and advances in sequencing technologies,
which we will discuss herein.
1.1. Influenza A
As members of the Orthomyxoviridae family, IAVs are negative-sense single-stranded
RNA (-ssRNA) viruses [18]. Influenza strains vary from seasonal variants which cause
a significant health care burden, to pandemics such as the Spanish Flu which killed an
estimated 50 million people from 1918 to 1919 [19]. Influenza circulates not only in the
human population, but in species such as birds, pigs and cats [20]. Two major obstacles
towards effective Influenza protection and treatment are antigenic shift and antigenic drift,
which are mechanisms which, through mutation or gene reassortment, can functionally
change Influenza biology. Antigenic drift, which also applies to other viruses such as
Flaviviridae and Coronaviridae family members, is the accumulation of point mutations due
to the error-prone virally encoded RNA-dependent RNA polymerase used to generate
new copies of the genome during replication [21]. Antigenic shift allows the formation of
new Influenza subtypes through reassortment of surface antigens haemagglutinin (HA) or
neuraminidase (NA) and is facilitated by the segmented genome of Influenza. Antigenic
shift occurs when an animal is infected with two or more different strains of Influenza virus,
enabling reassortment of HA and NA viral RNA segments and leading to a novel Influenza
strain to which the population is completely naïve [21]. This resulted in the first pandemic
of the 21st Century: swine-origin IAV [22]. The prediction of mutant strains of IAV that are
likely to arise is therefore imperative for prophylaxis and control, and the predictive power
of DMS can be utilised for the identification of animal viruses with zoonotic potential,
or to predict escape mutants that are insensitive to otherwise effective adaptive immune
responses or antiviral therapies.
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1.2. Flaviviridae
The Flaviviridae family of RNA viruses comprises multiple positive-sense single-
stranded RNA (+ssRNA) enveloped viruses, including hepatitis C virus (HCV), Dengue
virus (DENV) and Zika virus (ZIKV) [23]. These viruses have enormous impact around
the globe, with DENV alone infecting approximately 390 million people each year [24].
For most Flaviviridae (and viruses in general), no therapeutics or vaccines exist, with
exceptions for vaccines being yellow fever virus [25] and Japanese encephalitis virus [26].
In addition to furthering our understanding of basic Flaviviridae biology, DMS has enabled
the construction of a vaccine candidate for ZIKV, which will be discussed later.
1.3. SARS-CoV-2
The Coronaviridae family of positive-sense single-stranded RNA (+ssRNA) viruses
features several clinically relevant viruses including Middle East respiratory syndrome-
related coronavirus (MERS-CoV), Severe Acute Respiratory Syndrome Coronavirus (SARS-
CoV), and the current pandemic SARS-CoV-2, all of which have emerged in the past two
decades [27], as well as common cold-causing viruses such as HCoV-OC43 [28]. There
is currently a major global research effort to develop therapeutics and vaccines against
SARS-CoV-2 which ideally target regions of the virus that are incapable of mutational
escape, which would otherwise reduce the effectiveness of the treatment. DMS has been
employed to determine how mutants will affect SARS-CoV-2 neutralisation.
2. Reverse Genetics Systems to Study RNA Viruses
Due to the absence of DNA in the lifecycle of RNA viruses, the construction of cDNA
clones of infectious RNA viruses has become an incredibly important tool in studying
their lifecycle. Generally, a reverse genetics system is comprised of genomic viral RNA
that is reverse-transcribed into cDNA and then cloned into a plasmid, allowing for stable
propagation of a virus genome within bacteria or yeast. The plasmid can then be easily
manipulated by standard molecular methods, with the introduction of mutations and tags,
or the removal of segments of the genome [29].
There are multiple key requirements for an infectious (+)RNA virus cDNA clone.
A common approach involves incorporation of a DNA-dependent RNA polymerase pro-
moter at the 5′ end of a cloned viral genome to enable in vitro transcription of infectious
viral RNA via a corresponding RNA polymerase, with or without a type I 5′ cap structure,
if required. This is commonly achieved using bacteriophage promoters/polymerases such
as those of T7 and SP6. Produced RNA can then be purified and transfected into cells to ini-
tiate the viral replication cycle. A constitutive promoter such as a human cytomegalovirus
[HCMV] promoter can also be utilised, with viral RNA produced by host Polymerase II
after direct transfection of a full length cDNA clone into cells. As it is necessary to produce
viral RNA with precise ends, a self-cleaving hepatitis delta or hammerhead ribozyme
or a T7 terminator sequence may be added to the 3′ end of the viral genome to enable
generation of authentic 3′ ends [30,31]. Alternatively, a unique restriction endonuclease
site can be inserted at the 3′ end for plasmid linearization [32]. Some of the limitations of
these plasmid systems are instability in bacteria, due to the presence of cryptic bacterial
promoters and other factors leading to recombination during growth, and poor plasmid
yields [33]. As the preparation of mutant libraries involving plasmid clones of viral cDNA
often requires the pooling of a large number of bacterial colonies, it is important in DMS
studies to have a plasmid with both minimal recombination, to ensure that recombination
of the plasmid in bacteria does not affect cell culture experiments/analysis, as well as high
transformation efficiency to ensure that a library of sufficient mutational diversity can be
prepared. For these reasons, several bacterium-free approaches such as circular polymerase
extension reaction (CPER) [34] and yeast artificial chromosome (YAC) approaches, includ-
ing transformation-associated recombination (TAR) cloning in Saccharomyces cerevisiae [35],
have also been employed to enable efficient propagation and manipulation of (+)RNA
virus cDNA clones. Similarly, bacterial artificial chromosome (BAC) systems and modified
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plasmid DNA clones with features designed to minimise viral cDNA recombination and
toxicity in bacteria have also been applied to various reverse genetics systems for (+)RNA
viruses [31]. The reliability and ease of manipulation of viral cDNA using these systems
are important determinants of the success of DMS experiments.
Many significant hurdles were encountered during the construction of an Influenza
reverse genetics system. The Influenza genome comprises eight negative-sense ssRNA
segments [18]. Due to the negative-sense genome, the viral RNA is not sufficient for
initiation of viral replication, with the presence of multiple viral proteins being required to
begin the viral lifecycle [18]. The eight vRNAs must colocalise with this protein machinery
within the nucleus for initiation of infection [18]. Many reverse genetics systems have been
developed to overcome these difficulties, with the two main categories comprising helper
virus-dependent and -independent systems. Please see the review by Neumann et al. for a
more in-depth analysis of the history of Influenza reverse genetics systems [36]; and for
detailed documentation of these systems, please see the review by Engelhardt et al. [37].
Reverse genetics systems exist for many Flaviviridae species. Unlike Influenza A, the
construction of infectious clones for Flaviviridae was, at the time, hindered more by the lack
of available technologies such as high-fidelity PCR, instead of the fundamental biology
of the virus. Construction of these systems is often considered as relatively straightfor-
ward although, as detailed above, challenges in genome construction due to repetitive
elements, toxicity in E. coli and associated instability and recombination in E. coli are well-
documented. For a history of Flavivirus reverse genetics systems, please see the review by
Aubry et al. [31].
A reverse genetics system has recently been developed for SARS-CoV-2 [35]. However,
as no DMS experiments have been performed to date using a reverse genetics system for
the virus, we will not discuss this further. However, we highlight this as a potential area
for future DMS studies.
Reverse genetics systems have traditionally been used in low-throughput mutational
studies, to analyse the effect of single point mutations. Coupling reverse genetics with
deep sequencing and random mutagenesis has allowed for high-throughput mutational
studies, with analysis of hundreds of thousands of mutants being made possible in a
single experiment. In the following sections, we discuss the technologies which have been
essential in enabling DMS studies.
3. Next-Generation Sequencing
Advances in next-generation sequencing (NGS) have been crucial to the development
of DMS as a tool in the field of molecular virology. The first generation of sequencing
consisted mainly of Sanger sequencing and the Maxam and Gilbert technique. The second
generation of sequencing introduced mass parallelisation of reactions. The current genera-
tion of sequencers enable real-time, single molecule sequencing [38]. We will discuss three
commonly used platforms in DMS studies; Pacific Biosciences (PacBio) Single Molecule
Real-Time (SMRT) sequencing, Oxford Nanopore Technologies (ONT) real-time sequenc-
ing, and the Illumina short-read sequencing-by-synthesis technology, which is part of the
second generation of sequencing. [39]. For further in-depth detailing of the latest advances
in NGS, please see the review by Goodwin et al. [40].
3.1. Single-Molecule Long-Read Sequencing
Produced by Pacific Biosciences, PacBio SMRT technology (henceforth referred to
as SMRT) utilises a sequencing by synthesis approach. Initially, the DNA is fragmented
into pieces several kilobases in length and the addition of hairpin adaptors to the DNA
results in the formation of a circular SMRTbell DNA conformation. Next, the circular DNA
is introduced to a flow cell lined with picolitre wells with a transparent bottom (a zero-
mode waveguide) and a DNA polymerase enzyme fixed to the bottom of the well. The
polymerase then incorporates a fluorescently tagged nucleotide into the elongating DNA
strand, and the fluorescent signal emitted by the individual nucleotide being incorporated
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is recorded by a camera. Finally, each fluorophore is cleaved by the polymerase and
diffuses before the next read occurs. A major advantage of this technology is that the
circular SMRTbell DNA conformation allows for many rounds of sequencing of a single
DNA fragment, producing an accurate circular consensus sequence [41] (Figure 1).
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The Oxford Nanopore system (henceforth referred to as ONT) sequences DNA in a
unique manner. DNA is fragmented into pieces of several kilobases in length, then a motor
protein and a hairpin adaptor are added to either side of the DNA. A leader sequence
directs the DNA to a pore embedded in an electrically resistant membrane, and the motor
protein allows ssDNA to be pulled through the aperture of the pore. Simultaneously, an
electric current passes through the pore protein. As the ssDNA passes through the pore, a
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characteristic disruption of the electrical current occurs, dependent on the multiple bases
present in the pore. By analysis of this disruption, a DNA sequence can be identified by
its unique ‘k-mer’, which can be translated into a sequence (for example, AAGT will have
a distinct disruption compared to AGAT). The hairpin adaptor allows for bidirectional
sequencing of the DNA fragment, and the read from the forward and reverse strands can
be used to generate a consensus sequence [42] (Figure 2).
3.2. Illumina Sequencing by Synthesis
Used in Illumina sequencing instruments, DNA molecules are sheared to ≤300 base
pair fragments then ligated to adapter sequences which allow for hybridisation to com-
plementary oligonucleotides present in nanowells across a patterned flow cell. The DNA
fragments are amplified via bridge amplification, resulting in clonal clusters of DNA. Sub-
sequent addition and imaging of fluorophore-labelled terminator nucleotides allows for
highly parallel sequencing [43] (Figure 3).
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3.3. Next-Generation Sequencing Technologies: A Comparison
The main limitation of Illumina short-read technology in DMS studies is the short-
read length. Viral segments for analysis are often much longer than the read length of
the instrument. If two distant mutants are present in a single viral genome, and a specific
phenotype is observed, it is difficult to determine without further experimentation if
they are acting in a pairwise manner or if a single mutation is wholly responsible for
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the phenotype. Thus, pairwise epistatic mutations are not always resolvable using short-
read technology. A partial solution to this problem is to create multiple adjacent mutant
libraries of short lengths, ‘tiling’ across a gene, to restrict epistatic mutations to within a
readable window [44]. Alternatively, subassembly can be utilised. In this approach, tagging
each template molecule with a unique DNA barcode or ‘unique molecular identifier’
(UMI) allows for the grouping and analysis of multiple short reads on the basis of their
original template molecule [45]. Resolution of distant mutants is only possible using third
generation long-read sequencing strategies, offered by both SMRT and ONT.
Of the long-read sequencing platforms, SMRT is far more common than ONT in DMS
studies, likely attributed to its higher accuracy. The circular SMRTbell DNA conformation
allows for increased sequencing depth (how often a base is sequenced on average) to form
a consensus sequence, as the SMRTbell can be repeatedly sequenced. Errors in PacBio
sequencing are distributed randomly, and therefore the accuracy increases with increased
reads of a single SMRTbell molecule [46]. Oxford Nanopore sequencing utilises dsDNA
fragments, but does not allow continuous sequencing. A consensus sequence can be
formed by sequencing one strand of dsDNA, followed immediately by the complementary
strand, referred to as 1D2 sequencing, though the accuracy is somewhat limited compared
to PacBio and Illumina strategies [46]. Interestingly, a recent study has reported a high-
throughput amplicon sequencing approach that combines UMIs with PacBio or ONT to
enable generation of high-accuracy single-molecule consensus sequences for large DNA
regions [47]. This and similar approaches will help to overcome compromises in accuracy
that have previously been associated with the above long-read sequencing strategies. To
date, however, Illumina sequencing remains the most commonly used platform in DMS
studies due to its cost-effectiveness and high levels of accuracy.
4. Deep Mutational Scanning: Library Construction
As mentioned previously, the first step in a DMS experiment is the construction of a
mutant library. Multiple approaches have been developed and applied to mutant library
generation, which we will briefly describe below.
The simplest and most cost-effective method is error-prone PCR. In this method,
one or more polymerases are employed to exponentially amplify a region of DNA, with
initial template amount and cycle number varied to optimise mutation rate [48]. Taq DNA
polymerase, a popular error-prone polymerase, has a reaction buffer-dependent mutation
rate of roughly 8 × 10−6 errors/nucleotide [49]. However, the use of Taq polymerase alone
in library construction is limited by the mutants generated being dominated by AT→ GC
transitions and AT→ TA transversions, at approximately 2-4x the mutation rate of G and C
residues. A polymerase named Mutazyme DNA polymerase has a 2-4x stronger preference
for GC→ AT transitions and GC→ TA transversions [50]. In combination, these enzymes
can be used to produce a relatively unbiased mutant library with a somewhat controllable
mutation rate. A major drawback of this method is that not all amino acid residues are
accessible with single-nucleotide polymorphisms [51]. Additionally, this technique can
often result in multiple mutations present in a single DNA fragment that can confound
results, especially when using short-read sequencing strategies as mentioned earlier.
First described in virology studies by the Bloom lab in an Influenza nucleoprotein (NP)
study, synthetic oligonucleotides were designed to contain a randomised triplet for each
codon present in the gene, with 16 leading and lagging nucleotides that anneal specifically
to the NP gene, as well as the reverse complement of these oligonucleotides. Using a series
of joining PCR steps and restriction enzyme cloning, a product pool containing all possible
amino acid mutations of NP was cloned into an Influenza reverse genetics system [6]. When
designing oligonucleotides with randomised triplets, codon usage should be considered.
NNK degeneracy (N: Ade/Cyt/Gua/Thy, K: Gua/Thy) encodes all amino acids, while
NDT (N: Ade/Cyt/Gua/Thy, D: Ade/Gua/Thy, T: Thy) and DBK (D: Ade/Gua/Thy,
B: Cyt/Gua/Thy, K: Gua/Thy) each encode 12 amino acids, feature no stop codons and
exhibit all major biophysical types, while potentially decreasing workload. However,
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with decreased coverage, the amount of interesting variants will also be reduced [52].
This method is more costly compared to the error-prone PCR method, but can be used to
generate libraries with complete mutational coverage.
A synthetic approach to mutant library generation is also available. Gene synthesis
begins with oligonucleotide construction. These are designed such that adjacent oligonu-
cleotides in the final product contain overlapping sequences. The overlap results in a
DNA duplex which, through an assembly reaction with DNA polymerase, results in the
construction of the gene of interest [53]. Multiple methods allow for controlled or ran-
domised insertion of mutants into a gene. For example, the “Spiked Genes” method uses
oligonucleotides spiked, or interspersed, with mutants to create a pooled mutant frag-
ment [54]. Synthetic construction of multiple types of mutant libraries is possible through
commercially available gene synthesis services. Available mutant library types include
controlled randomised libraries, scanning alanine mutagenesis libraries, scanning codon
mutagenesis libraries and others.
An additional type of mutant library discussed in this review is the transposon
insertion library. This is facilitated by a transposase protein, such as Tn5, Tn7 or MuA that
recognizes the ends of a transposon, or a mobile DNA element, and forms a protein-DNA
complex termed the ‘transpososome’. This complex catalyses cleavage of target DNA at a
random site (although evidence of insertion bias exists [55]), and joining reactions allow
for the introduction of the transposon into a DNA template. For many applications, the
transposon is engineered to feature an antibiotic resistance gene, allowing for selection of
genetic elements with successful transposon integration. In these systems the transposon
also features two identical restriction enzyme sites on each end of the DNA element.
Upon purification, the now-unique plasmids are digested with the required restriction
enzyme. Gel electrophoresis allows for the removal of the majority of the introduced DNA
element by size separation, with a small insertion remaining after ligation of the plasmid
backbone [56,57]. High-throughput random mutagenesis of a cloned viral genome paired
with deep scanning allows for incredibly powerful studies which can probe regions of
genomic flexibility and functionality.
5. Standard Deep Mutational Scanning Experiment Methodology
DMS experiments often follow a similar methodology. Using a reverse genetics sys-
tem, a mutant virus library is generated via a method such as randomised mutagenesis,
controlled site-saturation mutagenesis, or transposon mutagenesis. This library is often
initially amplified using bacteria, with a higher number of uniquely transformed plasmids
translating to increased mutational diversity. This library is transfected into cells, allowing
for the propagation of RNA replication-competent viral genomes, as well as production
of viral particles. Infection of naïve cells with virus-containing cell culture supernatants
allows for propagation of genomes which are capable of both RNA replication and in-
fectious particle production. Variant analysis by NGS is then key to identifying specific
variants which are present at higher or lower levels at certain stages of the viral lifecycle in
comparison to the initial input (Figure 4).
While not a major focus in this review, it is important to note that DMS studies of
individually expressed proteins have been highly informative, particularly in the context
of the interactions of viral glycoproteins with host receptors or neutralising antibodies.
For example, angiotensin-converting enzyme 2 (ACE2), the host receptor for SARS-CoV-
2 [58], has been analysed for mutants which enhance binding to the spike glycoprotein,
to explore the use of an engineered soluble ACE2 as a potential therapeutic [59,60]. The
binding of computer-generated miniprotein inhibitors [61] and ACE2 decoys [62] to the
spike glycoprotein has also been effectively optimised using DMS. A similar strategy was
used to optimise affinity and specificity of a computationally designed protein that targets
H1N1 Influenza haemagglutinin [63,64].
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6. Bioinformatic Tools for Deep utational Scanning Data Analysis and Visualisation
Multiple software packages are available which facilitate variant analysis. ‘dms_tools’ [65]
and ‘Enrich2’ [66] calculate amino acid preferences under a selective pressure. ‘dms-view’ al-
lows straightforward visualisation of DMS data in the context of a protein structure [67].
‘MaveDB’ (multiplex assays of variant effect database) provides a tool for sharing DMS
data analyses.
7. Deep Mutational Scanning Experiments
In this section, we will briefly describe several past applications of DMS i virology,
focussing on Flaviviridae family viruses, IAV and SARS-CoV-2. Transposon mutagenesis has
been applied to several viruses to identify genomic regions tolerant to small insertions. An
insertion with minimal impact on fitness indicates genomic flexibility, or high mutability,
at a specific area, which may allow for adaptation of the virus to a new environment.
Disruption of function from an insertion may also reveal a region of functionality within a
gene or protein. The identification of a region of insertional tolerance is often exploited
by incorporation of epitope tags or reporter genes for further research. DMS projects
focussing on single-nucleotide polymorphisms and codon mutagenesis have focussed on
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several biological aspects, including identifying determinants of viral tropism, epistatic
interactions, drug and antibody escape mutants, and residues critical to several biological
functions. It is important to note that the following summary is not a comprehensive list of
all DMS scanning projects. DMS has also been applied to viruses including Norovirus [68],
Venezuelan equine encephalitis virus [69], Measles virus [70], Paramyxoviruses [71], foot-
and-mouth disease virus [72], Epstein–Barr virus [73] and Human immunodeficiency
virus [74–79], and as mentioned previously, we focus mainly on studies of viral replicative
fitness and immune evasion.
7.1. Hepatitis C Virus (HCV)
7.1.1. Transposon Analysis
In a comprehensive early study by Remenyi et al., the Mu-transposon system was used
to insert 15 nucleotide (nt) sequences (of which 10 nt are transposon derived and 5 nt are
duplicated target sites) into an HCV plasmid based on the chimeric sequence of genotype
2a J6 and JFH1 viruses [80]. This mutant library was propagated in human hepatoma
Huh-7.5.1 cells, then passaged onto naïve Huh-7.5.1 cells to separately analyse genomes
capable of viral RNA replication and infectious particle production. Regions tolerant to
an insertion illustrate flexibility at the genomic level, and potentially highlight a region
non-essential for in vitro growth. P7 and non-structural protein 2 (NS2), each coordinators
of virus assembly [81], and envelope protein 2 (E2) were identified as potential areas for
insertion of a tag or small peptide with minimal costs to replicative fitness due to the
regions of high genomic flexibility uncovered. The impact of NS4B transposon insertions
on infectious particle production helped to reveal a previously unknown functional region
of NS4B which was suggested to play a role in the viral lifecycle post-RNA replication.
In a subsequent study by the same group, a similar methodology was used to assess
insertions that confer sensitivity to the antiviral cytokine Interferon alpha (IFN-α) [82].
After two rounds of passage in Huh-7.5.1 cells in the presence or absence of IFN-α, it
was observed that mutants conferring sensitivity to IFN-α were clustered in p7, the 3′
untranslated region (UTR) and non-structural protein 5A (NS5A), which is important
for viral replication, infectious virus particle production and modulation of host cell
signalling [83]. Eight IFN-α sensitive p7 insertion mutants were constructed for validation,
and revealed the role of p7 in immune evasion. An interferon-stimulated gene (ISG) cDNA
expression library screen demonstrated that 13 of these ISGs were particularly antiviral
against viruses with mutant p7 in comparison to wild-type p7. Amongst these ISGs, IFI6-16
was identified as a major target of p7-mediated immune evasion. Coimmunoprecipitation
was then used to show a direct interaction between p7 and IFI6-16, which was previously
unknown. Each of these DMS studies furthered understanding of the roles of HCV proteins
in infection.
7.1.2. Variant Analysis
In an important application of DMS towards understanding emergence of viral re-
sistance to antiviral drugs Qi et al. applied high-throughput variant analysis towards
understanding resistance to Daclatasvir [84]; a potent inhibitor of NS5A [85]. An NS5A
mutant library of the J6/JFH1 strain (genotype 2a) was prepared and passaged in Huh7.5.1
cells in the presence or absence of daclatasvir over 2 passages, before analysis by NGS.
Drug selection resulted in selection of drug-resistant mutants at NS5A residues 28, 31, 38,
92 and 93, and increased drug resistance of some mutants at four additional residues. These
escape mutants can be used to identify daclatasvir-resistant strains of HCV [86]. In support
of this methodology, many of these resistance mutations have been identified in numerous
in vitro and clinical studies of HCV resistance to Daclatasvir and related inhibitors [87].
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7.2. Zika Virus (ZIKV)
7.2.1. Transposon Analysis
In the first published study involving high-throughput mutational analysis of ZIKV
a transposon insertion mutant library was generated for the ZIKV MR-766 strain [88].
Human embryonic kidney 293T (HEK 293T) cells were used to propagate the virus, then
naïve African green monkey kidney Vero cells were infected with viral supernatants
over two rounds. The first pool of selected viral RNA, reflecting viral RNA replication
requirements in HEK 293T cells, showed high levels of flexibility in the structural proteins
Envelope (E), precursor membrane (prM) and capsid (C), and also non-structural protein
1 (NS1), which is essential for ER remodelling and RNA replication [89]. The third pool,
consisting of infectious particle production-competent genomes, displayed most flexibility
in the structural proteins. Some insertions present in NS1 rendered the virus incapable
of infectious particle production while enhancing viral RNA replication capacity. In this
context, an insertion after amino acid 174 resulted in >650-fold enrichment in the initial
HEK 293T cell viral RNA population compared to the input RNA library yet was not
present in the Vero cell populations. Together, this study revealed regions of genetic rigidity
in the ZIKV genome across multiple lifecycle stages.
7.2.2. Variant Analysis
Envelope
Several mutational analyses of the ZIKV Envelope (E) protein have been performed.
An envelope mutant library for the MR766 ZIKV strain was constructed by Sourisseau et al.
to examine how mutants affect viral neutralisation by monoclonal antibodies [90]. The
MR-766 strain was first tested for the effects of mutations on viral fitness, with a focus on
infectious particle production in Vero cells. After validation, mutational antigenic profiling
was performed, whereby the selective pressure of a neutralising antibody results in the
enrichment of escape mutants present in the mutant library. Two antibodies were used
in this screen; ZKA64, which binds domain III of recombinant E protein, and ZKA185
which neutralises ZIKV without interaction with E protein, or any confirmed epitope [91].
Domain III of E protein is responsible for binding the cellular receptor, and is a common
target of potent ZIKV-neutralising antibodies [92]. The mutant ZIKV library was subjected
to these antibodies individually. ZKA64 and ZKA185 treatment resulted in strong selection
of several mutations that corresponded to sites within E, with mutants selected by ZKA64
present on envelope domain III, and mutants selected by ZKA185 present on envelope
domain II. Antibody escape resistance mutations A333T and T335E for ZKA64, and D67A
and K118R for ZKA185, were confirmed in follow-up neutralisation assays, illustrating
the usefulness and accuracy of mutational antigenic profiling for escape mutant predic-
tions, and demonstrating that antibody escape mutants can appear outside the receptor
binding domain.
The impact of Envelope on tropism using ZIKV strain PRVABC59 has also been
examined [93]. This study analysed mutant library growth in three cell types: C6/36
cells, derived from Aedes albopictus larvae, A549 adenocarcinomic human epithelial cells
and hCMEC/D3 cells, a human blood–brain barrier endothelial cell line. NGS analysis
revealed that a mutation at N154, an N-linked glycosylation site on the ZIKV envelope
protein, resulted in a significantly higher fitness of ZIKV in mosquito cells, but not in
human cells. Additionally, ablation of glycosylation through mutations surrounding the
N154 position enhanced viral entry into C6/36 cells, resulting in increased levels of viral
replication. DC-SIGN is a known viral entry factor for ZIKV that is not expressed in 293T
cells such that overexpression of DC-SIGN in 293T cells enhances ZIKV infection [94].
A comparison between wild-type ZIKV and ZIKV glycosylation mutants showed that,
with overexpression of DC-SIGN, infection of 293T cells by the glycosylation mutant ZIKV
was significantly diminished compared to wild-type ZIKV, demonstrating the requirement
of N-linked glycosylation of E in viral entry into mammalian cells, despite the resultant
loss of fitness in mosquito cells.
Viruses 2021, 13, 1020 13 of 23
In a similar study into cell tropism, a mutant library for the C-terminal of the E protein
of ZIKV (PRVABC59) was prepared and grown in Vero and C6/36 cells for 8 and 13 days,
respectively, to identify host-adaptive substitutions [95]. In C6/36 cells, mutants K316Q
and S461G were preferentially selected. The K316Q/S461G virus replicated less efficiently
in a selection of human cell lines, with lower levels of cytotoxicity compared to wild type,
while no change was seen in C6/36 and Aag2 mosquito cell lines. This combinatorial
mutant was determined to decrease the thermal stability of E, and as mosquito cell lines
are typically grown at a lower temperature (28 ◦C) than human cell lines, the effect was
not observed in the mosquito cell line. ZIKV infection can result in severe developmental
defects in the brain [96]. The K316Q/S461G virus was used to infect induced-pluripotent
stem cell-derived human brain organoids. Development of these organoids infected with
the K316Q/S461G virus greatly decreased growth retardation in comparison to wild-type
ZIKV. Infection of interferon alpha receptor knockout mice showed attenuated infection by
the K316Q/S461G virus, and protection against a later wild-type ZIKV infection, indicating
its potential as an attenuated vaccine candidate.
7.3. Dengue Virus (DENV)
Transposon Analysis
To identify regions of genetic flexibility in DENV, our group applied the Mu trans-
posase system to generate a library of mutants containing single random 15 nt insertions in
a serotype 2 Dengue virus (DENV-2) genome (strain 16681) [97]. Analysing both viral RNA
replication and infectious particle production in Huh7.5 cells, non-structural protein NS1,
required for RNA replication [98] and virus assembly [10], as well as structural protein
capsid (C) demonstrated highest tolerance to the insertions. Lowest tolerance of insertions
was seen in structural protein prM and non-structural protein 2A (NS2A), which is essential
for virus assembly [99]. Across the genome, flexibility peaked at the C termini for C, E,
NS1, NS2B and NS4B, and at the N termini of NS3 and NS4B. These experiments allowed
for the tagging of NS1 with epitope tags and reporter proteins including FLAG, APEX2
and NLuc, with minimal loss of viral fitness in Huh7.5 cells.
A similar transposon mutagenesis study of DENV-2 (16681) was performed by
Perry et al. [100]. This study identified regions of genetic flexibility and enabled identifi-
cation of well-tolerated insertion sites within non-structural protein 4B (NS4B), which is
involved in membrane rearrangements [101], and C, which were utilised to create a DENV-
2 clone expressing HA-tagged capsid, incapable of infectious particle production, and a
replication-competent infectious DENV-2 clone expressing HA-tagged NS4B. Together,
these studies identified regions of genetic flexibility within DENV-2 and exploited this
information to generate infectious reporter virus tools.
7.4. Influenza A Virus (IAV)
7.4.1. Transposon Analysis
Transposon mutagenesis has also been applied to great effect with the Influenza
(H1N1) A/Puerto Rico/8/1934 strain [102]. Mutagenized viral genome segments were
transfected into HEK 293T cells, then viruses were passaged onto naïve Madin–Darby
canine kidney (MDCK) cells for two rounds. NGS analysis revealed that two genes were
tolerant to insertions; haemagglutinin (HA), an attachment factor and membrane fusion
protein [103], and non-structural protein 1, responsible for immune evasion [104]. The
mutant library was then grown in embryonated chicken eggs, to determine how the library
would perform under different environmental pressures. HA features a head and stalk
domain [105]. In chicken eggs, insertions in the head of HA were preserved, while mutants
present in the stalk domain were not tolerated. Analysis of these HA head insertion
mutants showed no loss of fitness and were found to occur at antigenic sites. The authors
hypothesised that this flexibility may reflect a strategy in evasion of host immune systems.
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7.4.2. Variant Analysis
Hemagglutinin and Neuraminidase
A major focus of IAV research is the functional analysis of NA, which aids virus
budding, and HA, as antigenic variation of these proteins is responsible for the limited
protection that vaccines provide against IAV infection [106]. Using a HA mutant library,
Thyagarajan et al. illustrated that the antigenic sites of Influenza (H1N1) A/WSN/1933 HA
are most tolerant to mutations, providing an explanation for Influenza’s rapid antigenic
evolution [107]. Similar effects were also reported in DMS studies by Wu et al. [108] and
Boud et al. [109]. Influenza (H3N2) A/Perth/16/2009 HA has also been subject to analysis
by DMS [110]. Interestingly, from these studies, mutational tolerance was demonstrated
to be higher in the HA head for H1N1 Influenza strains, while mutational tolerance was
higher in the HA stalk of H3N2 [110]. H3 virus DMS data was therefore shown to not be
suitable for prediction of H1 virus evolution, while similarly H1 virus DMS data was not
useful for prediction of H3 virus evolution.
Continuing research into HA and its immunogenicity, Doud et al. analysed the
effects of single HA mutations on broad and narrow antibody neutralisation [111]. Broad
neutralising antibodies are capable of neutralising multiple strains of a virus subtype, or
neutralising multiple types of Influenza virus, due to their targeting of conserved regions
of proteins, while narrow antibodies are strain specific [112]. Wild-type Influenza (H1N1)
A/WSN/1933 was shown to be neutralised by broad anti-RBS and anti-stalk antibodies,
and narrow anti-head antibodies. Doud et al. prepared HA mutant libraries of a lab-
adapted Influenza (H1N1) A/WNS/1933 strain carrying green fluorescent protein in the
PB1 segment and demonstrated that narrow anti-head antibodies as well as broad anti-
RBS antibodies were highly susceptible to single mutation escape mutants, while broad
anti-stalk antibodies were highly resistant to escape mutants.
Expanding on the single-strain studies of HA, multiple H3N2 IAV strains were inves-
tigated for strain-specific HA properties in a recent study by Wu et al. [113]. Five major
antigenic sites (A-E) exist for H3N2 HA [114]. To investigate antigenic site B, mutant li-
braries of H3N2 strains A/Hong Kong/1/1968, A/Bangkok/1/1979, A/Beijing/353/1989,
A/Moscow/10/1999, A/Brisbane/10/2007, and A/North Dakota/26/2016 were prepared.
These libraries featured specific mutants of the HA receptor binding site at residues 156,
158, 159, 190, 193 and 196; each of which are known to affect receptor binding and viral
fitness [115–118]. A local fitness landscape of each mutant for each strain was constructed,
by transfection of the libraries into HEK 293T cells, and subsequent passage of the re-
sultant virus onto MDCK-SIAT1 cells. Analysis of the fitness landscape of these strains
illustrated that evolutionary constraints at these residues has changed during the natural
evolution of H3N2, indicating that deep mutational scanning data is not always suitable
for extrapolation across strains.
In another application of DMS to understand the evolution of IAV resistance to antivi-
ral selective pressures, Wu et al. investigated the antiviral therapeutic Oseltamivir [119],
which targets NA of various IAV strains [120]. Oseltamivir treatment has resulted in
the generation of Influenza (H1N1) H274Y neuraminidase mutants which decrease sen-
sitivity of the enzyme to oseltamivir. Despite fitness costs associated with the H274Y
mutant, the mutant has quickly become widespread [121]. Studying the Influenza (H1N1)
A/WSN/1933 virus with the H274Y mutant present, Wu et al. prepared a NA mutant
library. After successive passages in A549 cells, four mutants were discovered which either
fully (R194G, E214D) or partially (L250P, F239Y) restore H247Y A/WSN/1933 virus to
wild-type fitness levels without restored susceptibility to oseltamivir. This study illustrates
the power of DMS to understand and predict drug-resistant mutant strains and second site
mutations that restore fitness of otherwise attenuated drug-resistant virus strains.
Polymerase
Another IAV machinery that has been the subject of DMS studies is the viral poly-
merase. One of the most comprehensive studies of this nature involved analysis of adap-
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tation of the complex from avian to human cells by Soh et al. [122]. The core of the
Influenza virus RNA polymerase consists of the polymerase acidic protein (PA) C-terminal
domain, polymerase basic protein 1 (PB1) and the N-terminal of polymerase basic protein 2
(PB2) [123]. PB2 is a known virulence determinant [124] and it has been shown that a single
amino acid substitution (E627K) allows avian IAV to replicate efficiently in mammalian
cells [125]. Bioinformatics analyses reviewing IAV sequence databases have revealed other
mutants which have facilitated host adaptation in the past [126,127]. However, these
databases are likely incomplete and limited to past outbreaks. To address these ambigu-
ities, Soh et al. constructed a PB2 mutant library to reveal mutants of Influenza (H7N9)
A/Green-winged Teal/Ohio/175/1986 PB2 which improve either polymerase activity or
viral replication in human A549 cells in comparison to avian embryo CCL141 cells, to
predict mutants which may allow expansion of transmission towards mammalian species.
Thirty-three previously undescribed adaptive mutants were discovered. These adaptive
mutations were clustered in patches, potentially revealing regions of PB2 responsible for
host cell interactions.
Ozawa et al. applied a novel DMS approach to investigate avian Influenza polymerase
mutant residues of PA, PB1 and PB2, and their effect on host range [128]. A virus possessing
vRNA of both avian Influenza (H5N1) A/Muscovy duck/Vietnam/TY93/2007 and a
laboratory-adapted Influenza (H1N1) A/WSN/33, including a partial HA deletion mutant
featuring GFP was constructed. Growth of the virus was therefore limited to HA-expressing
cell lines. Mutant libraries were generated for PA, PB1 and PB2. The mutant virus library
was grown in 293-HA cells, and the highest GFP-expressing 293-HA cells were individually
sorted by flow cytometry for infection of naïve MDCK-HA cells. Analysis of expression of
matrix protein by quantitative reverse transcription PCR was used to identify 90 viruses
for further analysis by deep sequencing. After additional testing, 11 mutants were further
characterised in lung and bronchial epithelial cells as well as chicken fibroblast cells, for
viral kinetics and polymerase activity, and then for viral replication and pathogenesis in
mice, identifying multiple mutants which may increase virulence in mammals.
Continuing the molecular interrogation of PA, Wu et al. coupled DMS with in
silico mutant stability predictions to identify functional regions of Influenza (H1N1)
A/WSN/1933 PA [129]. A PA mutant library of this strain was used to infect A549
cells, allowing identification of both functionally and structurally important residues. In
addition, a protein stability predictor, Rosetta, was used to identify residues of structural
importance [130]. Pairing these methods of analysis allowed exclusion of structurally im-
portant residues from residues that were deemed to be deleterious by DMS, isolating only
functional effects. The study identified multiple residues of PA which abolish polymerase
activity with no detectable destabilization effect, as well as residues with little impact on
polymerase activity, but a substantial decrease in infectious particle production. While
most mutational studies focus on conserved regions for protein functionality, which can
exclude species- and strain-specific functional residues, this study by Wu et al. illustrated
an unbiased means of determining residues that are strictly functionally important, as
opposed to structurally important.
Assorted Viral Proteins and DMS Applications
Another application of DMS that is gaining attention involves analysis of viral deter-
minants of sensitivity to innate immune responses. As an example of this, Ashenberg et al.
explored resistance to the antiviral host factor MxA [131]. IAV nucleoprotein (NP) forms
the viral ribonucleoprotein complex with vRNA and the heterotrimeric RNA-dependent
RNA polymerase, and acts as an elongation factor [123,132]. Antiviral host factor MxA
is known to suppress viral transcription through its interaction with polymerase PB2
subunit and NP [133]. IAV strains have been identified which either block interferon-
induced production of MxA, or, through adaptive mutations, directly confer resistance
to MxA [134,135]. Ashenberg et al. determined the impact of all mutant NP residues of
Influenza (H3N2) A/Aichi/2/1968 on MxA resistance in MDCK-SIAT1 canine kidney cells
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either wild type or constitutively expressing MxA. Twenty nine mutants impacting MxA
resistance were identified via the screen, with further analysis identifying mutants which
increase sensitivity, or increase resistance.
Viral resistance and sensitivity to the antiviral effects of interferons (IFNs) is an-
other emerging application of DMS methodology, as exemplified by a recent study by
Du et al. [136]. Many interactions between IAV and the host immune system, as well as
host evasion strategies, have long been a focus of interest [137]. Du et al. performed a
genome-wide mutant screen for Influenza (H1N1) A/WNS/1933 to discover mutants that
alter interferon sensitivity. Virus was grown first in HEK 293T cells, then passaged in
A549 cells in the presence or absence of type 1 interferon pre- and post-infection, directly
prior to analysis of mutant abundance. Twenty six missense mutations that decreased
relative fitness under interferon treatment were randomly selected for further analysis.
Eight mutants from viral polymerase subunit PB2, matrix protein M1 and non-structural
protein 1 were chosen for further investigation, and then combined to create an interferon-
sensitive virus. This mutant IAV showed no attenuation in IFN-deficient Vero cells, but
significant attenuation in IFN-competent A549 cells compared to the wild-type IAV strain.
Additionally, the virus was attenuated in IFN-competent mice and ferrets, but not IFN
AR-/- mice, and acted as an attenuated vaccine, protecting mice and ferrets from broad
viral challenges. This study therefore allowed the identification of potential attenuated
vaccine candidates.
Further exploring IAV’s capacity to evade immunity, Wu et al. constructed a mutant
library for the vRNA segment of Influenza (H1N1) A/WSN/1933 which encodes NS1 [138],
given the critical role of NS1 as an antagonist of the innate immune response [137]. The
virus was passaged in the presence or absence of type I interferon in A549 cells. Multiple
SNPs displayed >2-fold higher interferon sensitivity compared to WT virus. In particular,
D92Y of NS1 showed 12-fold higher sensitivity to the interferon treatment. This mutant
was demonstrated to disrupt a hydrophobic pocket on NS1, which appeared to be critical
for anti-interferon activity. Further research demonstrated a critical role for the domain in
inhibition of RIG-I ubiquitination, a requirement for functional interferon signalling [139].
DMS is an ideal technique for discovery of single-residue changes that impact on viral
fitness. However, it can be challenging to investigate paired mutants of significance, even
if the mutants happen to be present on a single genome within a DMS experiment dataset.
Wu et al. combined a high-throughput genetic study with analysis of naturally occurring
sequences to identify a compensatory mutation in matrix protein M1 of IAV [140]. M1 acts
as an endoskeleton for the virus [141] and aids virus budding [142]. Transfection of HEK
293T cells with Influenza (H1N1) A/WNS/1933 with a mutant M segment, followed by
infection of A549 cells allowed identification of deleterious mutants. Thirteen deleterious
mutants were validated, and it was found that 3 of these were prevalent in nature, including
M1 Q214H. The software CAPS (Coevolution analysis using protein sequences) allows for
identification of co-evolving amino acids with a time-dependent analysis of the evolution
of pairs of amino acids from a changing sequence [143]. The analysis using CAPS revealed
that M1 214 coevolves with residues 121, 207, 209 and 214. The A209T mutation was found
to be compensatory for Q214H, revealing a novel pairwise epistatic interaction.
7.5. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Variant Analysis
The recent devastating outbreak of SARS-CoV-2 prompted the application of DMS to
investigation of binding of the viral spike protein to the angiotensin-converting enzyme 2
(ACE2) receptor [144]. Specifically, this study explored the effects of all amino acid muta-
tions of the receptor-binding domain (RBD) of a Wuhan-Hu-1 SARS-CoV-2 isolate on its
interaction with angiotensin-converting enzyme 2 (ACE2) to identify potential targets of
future antiviral strategies [145]. Two mutant libraries were prepared and expressed in a
yeast-surface display platform. RBD mutant expression was measured using a fluorescent
tag and sorted by flow cytometry based on expression levels into bins for analysis by deep
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sequencing. ACE2 binding was then measured by incubation of cells with fluorescently la-
belled ACE2, which was separated by flow cytometry into bins for further deep sequencing.
Analysis revealed considerable mutational tolerance of RBD for ACE2 binding and normal
expression levels. Mutants enhancing affinity for ACE2 were found at RBD sites Q493,
Q498 and N501. After publication, the SARS-CoV-2 variant VOC-202012/01, containing
an N501Y mutant, spread rapidly throughout the UK and South Africa, indicating the
real-world applicability of DMS [146]. In a follow up study, these RBD mutant libraries
were tested for escape from 10 human monoclonal antibodies [147]. Escape mutants were
identified using the yeast display platform model, with FACS determining ACE2 binding
levels. Most escape mutants appeared at the receptor-binding motif, where ACE2/RBD
contact residues are present. Negative-stain electron microscopy was used to determine
antigenic regions of the RBD for each antibody. This information allowed prediction of
effective antibody cocktails which do not allow enrichment of escape mutants
8. Concluding Remarks
DMS is an incredibly powerful tool for rapid and high-throughput mutational analysis
of viral proteins and genomes, and the above studies have illustrated the plethora of
applications that DMS offers to virology. DMS has allowed the construction of attenuated
vaccines, evolutionary studies, identification of functional regions of proteins, prediction
of mutants that increase host range and many other applications. As the feasibility of
NGS increases due to decreases in the cost of such studies, we will likely have a very
detailed view of the impact of point mutations for many viral genes. We hope that the
recent development of bioinformatic tools and databases which facilitate visualisation and
sharing of gathered DMS data will enable and encourage researchers to utilise existing
data for further experimentation, akin to the Protein Data Bank. The DMS-based discovery
of a SARS-CoV-2 N501 RBD mutant with enhanced ACE2-binding affinity, prior to its
natural appearance as a highly trasmissible variant reinforces the utility of DMS. However,
it also illustrates the need for strict biosafety measures in the field, in order to prevent the
accidental or intentional release of laboratory-created gain-of-function mutants. It has been
suggested that publication of specific gain-of-function mutations should be regulated to
ensure they are not recreated and misused, with data available on request. Alternatively,
as some have argued, studies which may produce gain-of-function mutations in viruses
with pandemic potential should be carefully scrutinised and regulated. For additional
reading, we refer to two Editorials for further thoughts on the ethical considerations of
gain-of-function experiments [148,149].
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